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Abstract
The Respimat® Soft Mist™ inhaler (SMI) has recently been improved, with a re-usable device replacing the
disposable version. Certain countries are currently phasing out the disposable inhaler. This study aimed to
assess patient satisfaction with and preference for the re-usable device. This 4–6-week, multicentre,
open-label, prospective, real-world, non-interventional study was conducted across six European countries.
Patients with chronic obstructive pulmonary disease were enrolled between October and December 2019, in
three cohorts: (1) currently using the re-usable Respimat SMI; (2) switched from disposable Respimat SMI at
study entry; and (3) naı̈ve to any Respimat SMI. Patients were assessed using the Patient Satisfaction and
Preference Questionnaire (PASAPQ) and Ease of Handling Questionnaire. In total, 262 patients were
enrolled. At follow-up, the mean PASAPQ score was 83.3/100 overall, with similar results across all three
patient cohorts. Most patients were ‘satisfied’ or ‘very satisfied’ with the re-usable device. The overall score for
willingness to continue using the device was 87.8/100. In total, 13 adverse events were recorded, none of which
was classified as serious. This study provides real-world evidence for practitioners to start patients on
Respimat re-usable, irrespective of a patient’s prior experience with this inhaler.
Plain language summary
Inhalers are often used to treat patients with chronic obstructive pulmonary disease (COPD). However, there
are many available, which can lead to confusion and poor inhaler technique. It is important for a patient to be
happy with their inhaler. This study looked at how patients liked the re-usable Respimat® Soft Mist™ inhaler vs.
their previous inhaler. It also asked whether they would be willing to continue using the device at the end of the
study period.After 4–6 weeks of using the re-usable device, patients reported that they were happy with the
inhaler and most would be willing to carry on using it.Overall, these results show that doctors can prescribe
Respimat re-usable to patients, even if the patient has not used the inhaler before.
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Introduction
The Respimat® Soft Mist™ inhaler (SMI), first avail-
able for patients with chronic obstructive pulmonary
disease (COPD) in 2004,1,2 was developed to overcome
limitations associated with earlier devices such as pres-
surised metered-dose inhalers (pMDIs), dry powder
inhalers (DPIs) and nebulisers.3,4 Objectives at the time
included avoiding propellant use and minimising the
need for patient coordination and inspiratory effort,
while optimising drug delivery to the lungs.3,4 The first
Respimat device was disposable, locking after the
labelled number of doses was reached, thereby requiring
a new inhaler each month.4 This overcame the problem
of patients continuing to use their inhaler when empty,
which was commonly reported with some DPIs and
pMDIs.5–8 Since then, development efforts have
focused on improving use of the Respimat SMI from
the patient’s perspective and allowing the inhaler to be
re-usable, while maintaining drug delivery to the lungs.3
Respimat re-usable,1,3 available for use in Europe
since 2019, represents an evolution of the original
disposable device following patient/physician feed-
back.1 The new device has improved usability (design
changes have enabled use with up to six cartridges), a
clearer dose indicator on each cartridge, a reversible
lock to allow for re-usability, along with a memory
aid to monitor the number of cartridges used.1 Studies
demonstrating the benefits of these design modifica-
tions have previously been published.1,9,10
Starting in March 2019, many countries across
Europe began phasing out the disposable device in
favour of the re-usable device. Given this trend, it is
important to assess the effect of switching device on
patient satisfaction and preference in real-world
settings.
This study aimed to assess the performance, con-
venience and ease of handling of the re-usable Respi-
mat SMI in routine clinical practice, as well as patient
satisfaction and preference.
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Methods
Study design
This multicentre, open-label, prospective, real-world,
non-interventional study (NIS)was conducted at20sites
across six European countries (Belgium, Denmark,
Finland, Germany, the Netherlands and Norway). The
study included patients with COPD who were pre-
scribed a re-usable Respimat SMI product. It included
three cohorts: (1) patients already receiving mainte-
nance treatment with the re-usable SMI (‘Re-usable’
cohort); (2) patients switching from the disposable to
the re-usable SMI (‘Switching’ cohort); and (3) patients
who had not previously used any SMI (‘Naı̈ve’ cohort)
(Figure 1).
Patients in the three cohorts were prescribed the
re-usable SMI, as per routine clinical practice at the par-
ticipating sites. Prescribing physicians received no gui-
dance regarding training of the participants on how to use
the re-usable device. Patients were permitted to use other
inhalers for maintenance treatment in addition to the
Respimat device; these were recorded and exploratory
analyses conducted based on this information.
Patients were enrolled between October and Decem-
ber 2019 by participating physicians involved in the
diagnosis, treatment and management of COPD,
including general practitioners and secondary care spe-
cialists. Each patient was followed prospectively from
the time of enrolment until the end of the study period
(4–6 weeks after enrolment), loss to follow-up or death.
The last patient was assessed in February 2020.
Study population
Eligible patients provided written informed consent
prior to inclusion in the study. Each country provided
study approval from a local ethics committee or a
central ethics committee (see Supplemental material).
This study is registered on ENCePP (EUPAS30293).
Patients were enrolled if they had a diagnosis of
COPD, were aged 40 years or older, were newly pre-
scribed or currently receiving Respimat SMI products
(Spiriva® 2.5 mg, Striverdi® 2.5 mg or Spiolto® 2.5 mg/
2.5 mg inhalation solution) and were literate in one of
the main languages of their country. In the prescribing
physician’s opinion, patients were unlikely to change
therapy during the observation period.
Patients were excluded if they used a disposable
Respimat SMI after study entry, experienced a severe
COPD exacerbation requiring hospitalisation in the
3 months prior to study entry, were currently partici-
pating in another clinical trial or NIS, or if they had an
Figure 1. Study design. COPD, chronic obstructive pulmonary disease; PASAPQ, Patient Satisfaction and Preference
Questionnaire; SMI, Soft Mist™ inhaler.
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impairment that raised concerns regarding their abil-
ity to complete the questionnaires.
Study outcomes and assessments
The Patient Satisfaction and Preference Questionnaire
(PASAPQ), validated in patients with asthma and
COPD,11 was used to assess patient responses. The
PASAPQ is a self-administered, multi-item instrument
that includes a performance domain (seven items:
question [Q] 1–5, Q10–11), a convenience domain (six
items: Q6–9, Q12–13), and standalone questions on
overall satisfaction (Q14) and willingness to continue
with an inhaler (Q15) (see Supplemental material).11
Each PASAPQ item has Likert-type response
options ranging from 1 to 7 (1 ¼ very dissatisfied to
7 ¼ very satisfied). The PASAPQ total score is the
sum of the 13 performance and convenience domain
items, transformed into a 0–100 (least–most) point
scale, with higher scores indicating greater satisfac-
tion. To calculate a domain score, the patient must
have answered at least half of the domain items, with
the total score calculated when both the performance
and convenience domains had computable scores.
For Q14 (overall satisfaction), scoring ranged from 1
to 7 (very dissatisfied to very satisfied), and for Q15
(willingness to continue using the device), scoring ranged
from 0 (not willing) to 100 (definitely willing), with val-
ues60 considered to represent willingness to continue.
The PASAPQ was administered at study entry for
the ‘Switching’ cohort and at follow-up for all cohorts
(Figure 1). The minimum important difference (MID)
was defined as 8–10 points.11
The Ease of Handling questionnaire was adminis-
tered at follow-up for all patients. This questionnaire,
developed by Boehringer Ingelheim (see Supplemen-
tal material), is based on close observations from the
Usability Tests of Respimat re-usable,1 and measures
patient satisfaction with 10 attributes of the device on
a seven-point Likert scale similar to the PASAPQ.
Supplementary question 1 of the Ease of Handling
questionnaire determined preference for the type of
Respimat SMI.
All patients were asked to report any adverse
events (AEs) at follow-up; an investigator then
assessed whether these could be classified as serious
adverse drug reactions (ADRs).
Statistical analysis
All analyses were conducted in the overall population
and in each of the cohorts, except for device
preference, which was assessed in the switching
cohort only. The primary outcome was the mean total
PASAPQ score at study end; secondary outcomes
included scores for the PASAPQ performance and
convenience sub-domains. In the switching cohort,
differences in the mean PASAPQ total score, and
performance and convenience scores, were assessed
at study entry and follow-up. Mean PASAPQ scores
were also analysed according to the number and type
of maintenance inhalers used during the study.
The full analysis set (FAS), comprising all enrolled
subjects who met the eligibility criteria and who received
at least one dose using the re-usable Respimat SMI, was
used for all primary and secondary outcome analyses.
All statistical tests were two-sided, assessed using a
significance level of 0.05; these were exploratory and
not adjusted for multiplicity. PASAPQ scores were
summarised using descriptive statistics for continuous
variables; overall satisfaction was summarised using
descriptive statistics for categorical variables. Ease of
handling attributes are presented as categorical vari-
ables. Statistical analyses for the switching population
included Wilcoxon signed-rank tests.
Results
Patient cohort
Overall, 262 patients were enrolled, of which 259 were
included in the FAS (133 re-usable, 70 switching,
56 naı̈ve). In total, 257 patients completed the study
(132 re-usable, 70 switching, 55 naı̈ve) (Figure 2).
Table 1 shows the patient demographics and base-
line characteristics of the FAS. Of these, 17.0% were
identified from primary care settings, 18.9% were
from settings providing both primary and secondary
care, and 64.1% were from secondary care facilities.
Information regarding previous device and medica-
tion use can be found in the Supplemental material.
The mean duration of participation for patients who
completed the study was 37.2 days (standard devia-
tion 6.6).
PASAPQ total score, performance and
convenience domain scores at study end
Overall, 255 patients completed the PASAPQ
(re-usable, n ¼ 131, switching, n ¼ 69; naı̈ve,
n ¼ 55). The mean total PASAPQ score was 83.3 out
of 100 (95% confidence interval [CI] 81.2–84.6), indi-
cating that patients were satisfied with Respimat
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re-usable. This was consistent across the three cohorts
(means: 81.6–84.3), the performance and convenience
domains (means: 82.4–84.7 and 80.1–84.2, respec-
tively) and the item scores individually (see Supplemen-
tal material).
In the switching cohort, the mean PASAPQ perfor-
mance and convenience scores increased from 80.9
and 79.3 at baseline to 82.9 and 80.1 at follow-up,
respectively, although these were not statistically
significant (Wilcoxon signed-rank test P ¼ 0.409 and
P ¼ 0.932, respectively) and did not meet the MID of
8–10 points.11 Factors such as instructions for use,
ease of cleaning and ease of holding the inhaler scored
higher at follow-up than at study entry.
Irrespective of other maintenance devices being
used during the study, mean PASAPQ scores and
performance and convenience scores were similar:
re-usable only, means 82.7–83.5 (n ¼ 144); re-usable
þ DPI, means 85.1–86.7 (n ¼ 45); re-usable þ MDI,
means 81.2–81.5 (n ¼ 64); re-usable þ MDI þ DPI,
means 97.2–100 (n ¼ 2) (see Supplemental material).
When analysed by age, median PASAPQ scores
were significantly higher in patients aged <65 years
compared with those aged 65 years (<65 years:
85.9, 65 years: 83.3; P ¼ 0.009), though the numer-
ical difference was lower than the MID.
PASAPQ satisfaction (Q14) and willingness to
continue (Q15)
The majority of patients (88.6%) were ‘satisfied’
(51.0%) or ‘very satisfied’ (37.6%) with Respimat
Figure 2. Patient disposition. aOne patient did not meet the inclusion criteria, and one patient met the exclusion criteria.
bPatient received disposable inhaler instead of Respimat re-usable. FAS, full analysis set; SMI, Soft Mist™ inhaler.
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Table 1. Patient demographics and baseline characteristics.
Re-usable (n ¼ 133) Switching (n ¼ 70) Naı̈ve (n ¼ 56) Overall (n ¼ 259)
Mean age, years (SD) 69.1 (7.59) 68.6 (8.58) 68.7 (7.69) 68.9 (7.86)
Gender, n (%)
Male 67 (50.4) 33 (47.1) 31 (55.4) 131 (50.6)
Female 66 (49.6) 37 (52.9) 25 (44.6) 128 (49.4)
Age at diagnosis, mean years (SD) 60.4 (9.62) 58.6 (8.96) 61.3 (9.74) 60.1 (9.49)
Duration of illness, mean years (SD) 9.1 (5.72) 10.54 (6.83) 7.83 (7.19) 9.21 (6.41)
Education level, n (%)
Elementary school 56 (42.4) 30 (44.1) 32 (58.2) 118 (46.3)
High school 66 (50.0) 34 (50.0) 18 (32.7) 118 (46.3)
University degree 10 (7.6) 4 (5.9) 5 (9.1) 19 (7.5)
Missing 1 2 1 4
COPD GOLD stage, n (%)
1 6 (4.5) 5 (7.1) 6 (10.7) 17 (6.6)
2 28 (21.1) 24 (34.3) 21 (37.5) 73 (28.2)
3 44 (33.1) 20 (28.6) 10 (17.9) 74 (28.6)




46 (34.6) 17 (24.3) 17 (30.4) 80 (30.9)
Care facility, n (%)
Primary 25 (18.8) 8 (11.4) 11 (19.6) 44 (17.0)
Primary/Secondary 22 (16.5) 19 (27.1) 8 (14.3) 49 (18.9)
Secondary 86 (64.7) 43 (61.4) 37 (66.1) 166 (64.1)
COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SD, standard deviation.
Figure 3. Overall satisfaction by cohort. PASAPQ question 14. The Overall Satisfaction item response values range from
1 (very dissatisfied) to 7 (very satisfied). PASAPQ, Patient Satisfaction and Preference Questionnaire.
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re-usable (Figure 3). Overall, 3.2% of patients
reported that they were very dissatisfied, dissatisfied
or somewhat dissatisfied with the re-usable inhaler
(range: 4.3% in the switching cohort to 2.3% in the
re-usable cohort).
Regarding willingness to continue using the
re-usable SMI, the overall mean score was 87.8
(95% CI 85.7–89.8), indicating that the majority of
patients would be willing to continue using the inhaler
(this was similar across all patient cohorts [means
84.1–89.1]; see Supplemental material).
Ease of Handling questionnaire
Overall, 255 participants completed the Ease of Han-
dling questionnaire (re-usable, n ¼ 131, switching,
n ¼ 69; naı̈ve, n ¼ 55). Of these, 254 responded to
Q8 on ‘overall ease of handling’: 91.3% of patients
responded that they were ‘satisfied’ (score ¼ 6) or
‘very satisfied’ (score ¼ 7) (re-usable 94.6%, switch-
ing 87.0%, naı̈ve 89.1%) (Figure 4), and 3.1% of
patients responded that they were very dissatisfied
(score ¼ 1), dissatisfied (score ¼ 2) or somewhat
dissatisfied (score ¼ 3) (range: 5.8% in the switching
cohort to 0.0% in the naı̈ve cohort).
For the other questions in the Ease of Handling
questionnaire, 89.8% of patients gave scores of 6 or
7 for recognising when they needed to replace the
cartridge (Q5), and 89.3% for the readability of the
dose indicator (Q4) and grip of the cartridge (Q2). For
the remaining questions, the percentage of patients
who gave scores of 6 or 7 ranged from 89.0% (for
recognising when to replace the inhaler [Q10]) to
77.2% (satisfaction with inserting a new cartridge
[Q3]) (see Supplemental material).
Patient preference (supplementary question 1)
In the switching cohort, 68 of the 70 patients
responded to the inhaler preference question. Of the
respondents, 57 (84%) preferred Respimat re-usable;
eight (12%) preferred the disposable device and three
(4%) indicated no preference.
Of the eight patients who reported a preference for
the disposable Respimat, five were enrolled from the
same site. The majority of the eight patients gave
PASAPQ scores >4 for the performance and conve-
nience items, indicating some level of satisfaction
with the re-usable device. Regarding Q15 of the
PASAPQ, ‘willingness to continue’, six of these
eight patients (75%) reported that they would
be willing to continue using Respimat re-usable (rat-
ings of 75 [n ¼ 1], 85 [n ¼ 1], and 100 [n ¼ 4],
respectively).
Regarding the Ease of Handling questionnaire,
scores among the eight patients who preferred the
Figure 4. Overall ease of handling of Respimat re-usable. Ease of Handling questionnaire (Q8). The Ease of Handling item
response values range from 1 (very dissatisfied) to 7 (very satisfied).
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disposable Respimat were lower for the additional
handling steps involved with the re-usable device.
Specifically, lower scores were reported for the steps
relating to cartridge replacement, including ease of
removing the clear base (Q1), inserting a new cartridge
(Q3), automatic detachment of clear base (Q6) and
automatic return to start-use position (Q7) (range:
4.75–4.88), compared with the overall population
(range: 5.77–5.94) and with switching patients who
preferred the re-usable device (range: 5.66–5.91).
Safety
In total, 13 AEs were reported, none of which was
classified as serious. These included one ADR (sore
throat) that resulted in treatment discontinuation in a
Respimat-naı̈ve patient.
Discussion
The present study shows that, in clinical practice,
patients report satisfaction with Respimat re-usable
in terms of performance, convenience and ease of
handling. Consistent levels of satisfaction were
reported among patients already using the device,
those who switched to the device from the disposable
device, and new users, as well as patients using mul-
tiple maintenance inhalers.
The current study supports previous data that
showed high patient satisfaction with SMIs,4,8,12,13
including studies using the PASAPQ and similar
questionnaires.13–15 Previous reports on satisfaction
using the PASAPQ have indicated that a score of
6.0 (or over 80.00 when transformed) indicates high
patient satisfaction.13–15 The mean PASAPQ total
score of 83.3 for the re-usable SMI was slightly higher
than that reported in a previous study evaluating the
disposable Respimat (80.7).14 These differences in
scores are within the MID.11
In the convenience domain, the switching cohort
reported slightly lower scores than other cohorts. As
these patients were required to switch from their
disposable Respimat inhalers, their perception of con-
venience may understandably be lower than in
patients who did not switch at study entry or who were
naı̈ve to the device. Despite this, their convenience
score was still high, with factors such as instructions
for use, ease of cleaning and ease of holding the inha-
ler scoring higher at follow-up than with their previ-
ous device. Responses to the PASAPQ question about
‘using the inhaler’ also improved at follow-up, in line
with follow-up results from the Ease of Handling
questionnaire. Therefore, switching from the disposa-
ble to the re-usable device appears to be associated
with high levels of satisfaction overall.
Regarding willingness to continue using Respimat
re-usable after study completion, the results were sim-
ilar across all three cohorts, with patients already on
the re-usable device having the highest mean score
(89.1) and Respimat-naı̈ve patients having a slightly
lower score (84.1). This may be due to their lack of
experience with the Respimat inhaler. The naı̈ve cohort
scored highest overall on device convenience (84.2),
followed by the re-usable cohort (83.7) and then the
switching cohort (80.1).
Patient satisfaction and correct inhaler use are
critically important for optimal drug delivery and can
predict favourable clinical outcomes.1,16,17 Ineffec-
tive training on an inhalation device can influence the
patient’s perception of the device performance;18,19
however, as this was an NIS, reflecting general clin-
ical practice, no guidance was given to the physicians
regarding training of the participants on the re-usable
device. The majority of the switching cohort (84%)
reported preference for Respimat re-usable at study
end, with 12% preferring the disposable device
and 4% reporting no preference. Of the 12% who
preferred the disposable device, 75% reported will-
ingness to continue using the re-usable device.
Respimat re-usable was developed in response to
feedback from patients.1,3 In the current study, patients
were most satisfied with the readability of the amount of
medication left, ease of inhaling and ease of use, as well
as ease of holding the device. Patients also scored steps
around cartridge replacement highly (including ease of
removing the clear base, inserting a new cartridge, auto-
matic detachment of the clear base and automatic return
to start-use position), but scored lower for other ques-
tions from the Ease of Handling questionnaire. As such,
these may be potential areas to highlight during patient
training at the time of inhaler initiation.
This study has a number of strengths, including the
use of a validated tool (PASAPQ) to assess patient
satisfaction. Furthermore, the large, multinational
study population is reflective of a real-world popula-
tion of patients with COPD (mean age 69.0 years in
the current study and 70.8 years in a study by Halpin
et al.),20 encompassing diversity in terms of inhaler
use (including type and multiplicity of inhalers). The
study included patients across a range of care settings
and Global Initiative for Chronic Obstructive Lung
Disease stages.
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This study does have some limitations, such as the
relatively small sub-groups. Additionally, due to the
short study duration, it is possible that all study parti-
cipants could not assess all aspects of device function-
ality. However, the mean study duration (37.2 days)
implies that a high proportion of participants com-
pleted more than 30 days of treatment, and therefore
had to replace the cartridge (see Q3 and Q5 of the
Ease of Handling questionnaire).
This study suggests that patients preferred the
re-usable device to their previous devices; however,
the important factor for consideration of medication
delivery to the lungs – inhaler technique – was not
assessed, with items 1 and 2 of the PASAPQ only
asking about the patient’s feeling and confidence that
the inhaled medication went to their lungs. Lastly, as
this was an open-label, non-randomised study, there is
the potential for selection bias, which may create
imbalances when comparing between the cohorts.
Information on cognitive function, psychological sta-
tus and patients’ level of social support was not col-
lected, and as such we were unable to assess the
impact of these factors on the patients’ ability to cor-
rectly use their inhalation devices.
Conclusions
Patients in this study reported high satisfaction with
the performance, convenience and ease of handling of
Respimat re-usable. This study provides real-world
evidence that can give practitioners confidence to
start patients on Respimat re-usable, irrespective of
a patient’s prior experience with the Respimat inhaler.
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